Filter results

Carcinogens clinical trials

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

View clinical trials related to Carcinogens.

Filter by:

Completed
Page 1

NCT ID: NCT02810431 Completed - Cancer Clinical Trials

Long Term Retention of Protspectively Obtained Biospecimens

Start date: December 22, 2011
Phase:
Study type: Observational

Background: This protocol is designed to have samples from closing protocols transferred to this protocol for long-term storage. The protocol is concerned with the retention of blood, plasma, serum, CSF, aspirates, bone marrow, ascites fluid, urine, saliva, PBMCs, skin, mucosal, tumor and healthy tissue samples from patients with cancer to support basic science and clinical research activities of the Medical Oncology Branch and other intramural Laboratories and Branches at the NIH Clinical Research Center and Center for Cancer Research. Objectives: To allow long-term storage of biospecimens collected during prospective clinical trials in patients with various cancer phenotypes, as needed to support the research activities of the Medical Oncology Branch and other Laboratories and Branches. Eligibility: Samples eligible for long-term retention must be from those who have signed consent for storage and retention of biospecimens. Design: Acquired samples will be barcoded and associated data will be entered into an encrypted computer software system, and securely maintained to protect patient identifiers. Samples are retained and made available to the original PI, or other Investigators with the original PI's permission, following submission and approval of a supplemental research protocol to the IRB or OHSRP.